A Mayo Clinic research team has challenged the accepted theory on the cause of sepsis -- a condition in which the body's cells generate fever, shock and often death. Sepsis is thought to occur when poisons from bacterial infection interfere with the cells. The Mayo researchers challenge that long-held concept with a new theory in an opinion piece in the current issue of Trends in Molecular Medicine http://www.sciencedirect.com/science/journal/14714914. Their findings suggest that sepsis begins with a change in certain cellular receptors that then provoke widespread inflammation, even in the absence of bacteria or their poisons.

"We think people have been focusing too exclusively on a single causal factor of sepsis for the last 150 years and, as a result, therapeutically aiming at the wrong target -- the bacteria and the poisons they produce," says senior author Jeffrey Platt, M.D. "That's why the death rate remains so high despite efforts to block the poisons."

The researchers define a new "first step" that initiates the sepsis syndrome cycle. In this step, a critical receptor for bacterial poisons and for some of the body's own substances is liberated from "natural suppression." Once free to function, the receptor can trigger the catastrophic cascade of events that is sepsis. The sepsis syndrome can occur during a bacterial infection, as the accepted medical principle holds, or -- as the Mayo Clinic team theory suggests -- it also can occur when substances the body makes act like the bacterial poisons. The Mayo investigators suggest that some or even many cases of sepsis may actually be caused by these normal body substances. The Mayo team argues that this new understanding of how sepsis arises could lead to new treatments for this major medical problem.

Significance of the Mayo Clinic Research

Approximately 700,000 cases of sepsis occur annually in the United
'"/>

Contact: Robert Nellis
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
7-Feb-2006

Page: 1 2 3
Related medicine news :

1. Clinical data suggest potential versatility of ALIMTA-based regimens in lung cancer
2. Susan G. Komen for the Cure and American Society of Clinical Oncology partner in national initiative
3. Clinical review -- A psychological approach to the management of irritable bowel syndrome
4. NHLBI Asthma Clinical Research Networks and ALA ACRC Network to present at ATS 2007
5. New Mayo Clinic MRI technology enables noninvasive liver diagnoses
6. Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
7. Elsevier launches the Clinics on ScienceDirect
8. Clinical guidelines for blood conservation during cardiac procedures developed
9. Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
10. Mayo Clinic research in cardiovascular disease presented at Experimental Biology 2007
11. Mayo Clinic study finds heart transplant patients benefit from new approach to immunosuppression